English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/215648
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorAdell, Albert-
dc.date.accessioned2020-06-30T16:31:30Z-
dc.date.available2020-06-30T16:31:30Z-
dc.date.issued2020-06-23-
dc.identifier.citationBiomolecules 10(6): 947 (2020)-
dc.identifier.issn2218-273X-
dc.identifier.urihttp://hdl.handle.net/10261/215648-
dc.description© 2020 by the author.-
dc.description.abstractN-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine (PCP), dizocilpine (MK-801) and ketamine have long been considered a model of schizophrenia, both in animals and humans. However, ketamine has been recently approved for treatment-resistant depression, although with severe restrictions. Interestingly, the dosage in both conditions is similar, and positive symptoms of schizophrenia appear before antidepressant effects emerge. Here, we describe the temporal mechanisms implicated in schizophrenia-like and antidepressant-like effects of NMDA blockade in rats, and postulate that such effects may indicate that NMDA receptor antagonists induce similar mechanistic effects, and only the basal pre-drug state of the organism delimitates the overall outcome. Hence, blockade of NMDA receptors in depressive-like status can lead to amelioration or remission of symptoms, whereas healthy individuals develop psychotic symptoms and schizophrenia patients show an exacerbation of these symptoms after the administration of NMDA receptor antagonists.-
dc.description.sponsorshipThis work was supported by the Instituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación (FIS Grants PI16/00217 and PI19/00170) that was co-funded by the European Regional Development Fund (‘A way to build Europe’). Funding from the Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Salud Carlos III is also acknowledged-
dc.language.isoeng-
dc.publisherMultidisciplinary Digital Publishing Institute-
dc.relation.isversionofPublisher’s version-
dc.rightsopenAccess-
dc.subjectNMDA-
dc.subjectDepression-
dc.subjectSchizophrenia-
dc.subjectSubunit-
dc.subjectGlutamate-
dc.subjectGABA-
dc.titleBrain NMDA Receptors in Schizophrenia and Depression-
dc.typeartículo-
dc.identifier.doihttp://dx.doi.org/10.3390/biom10060947-
dc.description.peerreviewedPeer reviewed-
dc.relation.publisherversionhttps://doi.org/10.3390/biom10060947-
dc.identifier.e-issn2218-273X-
dc.date.updated2020-06-30T16:31:31Z-
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0/-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderCentro de Investigación Biomédica en Red Salud Mental (España)-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100006751es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
Appears in Collections:(IBBTEC) Artículos
Files in This Item:
File Description SizeFormat 
Brain_Adell_Art2020.pdf2,14 MBAdobe PDFThumbnail
View/Open
Show simple item record
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.